AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 26908839
Drug: Gonadotropin suppression
RxNorm normalized name: Chorionic Gonadotropin
DrugBank: Chorionic Gonadotropin (Human) (DB09126)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Gonadotropin suppression (testosterone enanthate + levonorgestrel + 5α‐reductase inhibitor dutasteride)
Trial: 20688040
Drug: LEISH-F1+MPL-SE vaccine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LEISH-F1+MPL-SE vaccine (5, 10, or 20 μg recombinant Leishmania polyprotein LEISH-F1 antigen + 25 μg MPL-SE adjuvant)
Trial: 7531487
Drug: Vinorelbine (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vinorelbine (30 mg/m2 i.v. bolus weekly)
Trial: 26928845
Drug: Transdermal testosterone
RxNorm normalized name: testosterone Transdermal System
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal testosterone gel daily for 14 weeks
Trial: 26928845
Drug: Placebo gel
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo gel daily for 14 weeks
Trial: 23118021
Drug: Low-dose MDMA
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose MDMA (25 mg, plus 12.5 mg supplemental dose)
Trial: 23118021
Drug: Full-dose MDMA
RxNorm normalized name: Rho(D) immune globulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Full-dose MDMA (125 mg, plus 62.5 mg supplemental dose)
Trial: 10440423
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg in fasting state
Trial: 10440423
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg in fed state
Trial: 10440423
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg with antacid (Maalox 2 x 400 mg tablets 1 hour before dosing)
Trial: 10440423
Drug: Clopidogrel 75
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75 mg without antacid
Trial: 8558205
Drug: Buthionine sulfoximine
RxNorm normalized name: Buthionine sulfoximine
DrugBank: Buthionine sulfoximine (DB12870)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buthionine sulfoximine (BSO) 1.5 to 17 g/m2 intravenously every 12 hours for six doses, followed by melphalan (L-PAM) 15 mg/m2 intravenously 1 hour after the fifth dose of BSO in the second cycle.
Trial: 8558205
Drug: Buthionine sulfoximine
RxNorm normalized name: Buthionine sulfoximine
DrugBank: Buthionine sulfoximine (DB12870)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buthionine sulfoximine (BSO) at doses >= 13 g/m2.
Trial: 8558205
Drug: Buthionine sulfoximine
RxNorm normalized name: Buthionine sulfoximine
DrugBank: Buthionine sulfoximine (DB12870)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Buthionine sulfoximine (BSO) at various doses.
Trial: 1805152
Drug: 1 mg
RxNorm normalized name: biotin 1 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 mg vitamin K1 intramuscularly
Trial: 31246882
Drug: Cognitive-Behavioral Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cognitive-Behavioral Therapy for Insomnia (CBT-I) for 6 weeks
Trial: 29493402
Drug: Salmeterol/fluticasone Easyhaler
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salmeterol/fluticasone Easyhaler (two inhalations of 50/500 μg/inhalation strength)
Trial: 24923533
Drug: Comprehensive Geriatric
RxNorm normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Comprehensive Geriatric Assessment (CGA) conducted by a geriatrician before cancer treatment, participation of the same geriatrician in cancer treatment selection, a standardised geriatric therapeutic intervention designed by the same geriatrician, and geriatric follow-up for 24 months.
Trial: 22934526
Drug: Shengjing prescription
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Shengjing prescription
Trial: 8145097
Drug: Higher potency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher potency pancreatic enzyme preparations
Trial: 8145097
Drug: Pancreatic enzyme
RxNorm normalized name: Pancreatic enzyme
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pancreatic enzyme preparations
Trial: 8145097
Drug: Higher potency
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Higher potency preparations
Trial: 3463271
Drug: Calcium supplements
RxNorm normalized name: CALCIUM SUPPLEMENTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Calcium supplements (1 gram of elemental calcium)
Trial: 30290615
Drug: Closed-loop target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Closed-loop target-controlled infusion of propofol and remifentanil
Trial: 30290615
Drug: Manual target-controlled
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual target-controlled infusion of propofol and remifentanil
Trial: 26929604
Drug: Conventional treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional treatment and lung-protective ventilation strategy
Trial: 22839709
Drug: ω-3 polyunsaturated
RxNorm normalized name: OMEGA-3 POLYUNSATURATES
DrugBank: Omega-3 fatty acids (DB11133)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ω-3 polyunsaturated fatty acids (PUFA) 1 g/day for 6 months
Trial: 22839709
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (standard antiarrhythmic therapy without ω-3 PUFA)
Trial: 20346242
Drug: Combination DMARD
RxNorm normalized name: combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination DMARD therapy (COMBI) starting with sulfasalazine, methotrexate, hydroxychloroquine, and prednisolone
Trial: 20346242
Drug: Monotherapy (SINGLE)
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monotherapy (SINGLE) initially with sulfasalazine, with or without prednisolone
Trial: 19067892
Drug: N-acetylcysteine (NAC,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: N-acetylcysteine (NAC, 30-45 mg/kg/d)
Trial: 19067892
Drug: L-alanine
RxNorm normalized name: L-alanine
DrugBank: Alanine (DB00160)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: L-alanine
Trial: 16188807
Drug: Nebulization of
RxNorm normalized name: OIL OF CAMPHOR
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nebulization of 0.25 mg dexamethasone every 6 hours (group 1)
Trial: 14519708
Drug: Estrogen plus
RxNorm normalized name: estrogens
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Estrogen plus progestin (0.625 mg conjugated equine estrogens plus 2.5 mg medroxyprogesterone acetate)
Trial: 10561249
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg/d for 4 years plus Epirubicin (EPI) 50 mg/m² intravenously on days 1 and 8 every 4 weeks for six cycles
Trial: 10561249
Drug: Tamoxifen (TAM)
DrugBank: Tamoxifen (DB00675)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Tamoxifen (TAM) 20 mg/d for 4 years
Trial: 400734
Drug: Intravenous administration
RxNorm normalized name: intravenous administration set
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous administration of regular insulin
Trial: 27052787
Drug: Mediterranean diet
RxNorm normalized name: phentermine hydrochloride Oral Capsule [T-Diet]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mediterranean diet supplemented with nuts and pharmacological treatment
Trial: 22804250
Drug: Dulaglutide 1.0
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 1.0 mg
Trial: 22804250
Drug: Dulaglutide 0.1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dulaglutide 0.1 mg
Trial: 22804250
Drug: All dulaglutide
RxNorm normalized name: Dulaglutide
DrugBank: Dulaglutide (DB09045)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: All dulaglutide doses
Trial: 20410085
Drug: DAG oil
RxNorm normalized name: Daglutril
DrugBank: Daglutril (DB05796)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DAG oil (40 g/d)
Trial: 20410085
Drug: Control oil
RxNorm normalized name: SALICYLIC ACID 29.2 mg TOPICAL LIQUID [Acne Control oil-free Cleansing]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control oil (40 g/d)
Trial: 14686231
Drug: Treatment of
RxNorm normalized name: DRUGS FOR TREATMENT OF LEPRA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Treatment of active disease
Trial: 10747210
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 1 mg after surgery with PCA delivering morphine 0.2 mg h‐1, 0.2 mg per bolus.
Trial: 10747210
Drug: Epidural morphine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural morphine 1 mg plus ketamine 5 mg after surgery with PCA delivering morphine 0.2 mg + ketamine 0.5 mg h‐1, morphine 0.2 mg + ketamine 0.5 mg per bolus.
Trial: 7191313
Drug: Acemetacin (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Acemetacin (180 mg daily in three divided doses)
Trial: 7191313
Drug: Indometacin (150
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Indometacin (150 mg daily in three divided doses)
Trial: 20096136
Drug: Manual Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Manual Therapy according to the Utrecht School of Manual Therapy (MTU) for six weeks
Trial: 20096136
Drug: Physical Therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Physical Therapy (standard care, mainly active exercise therapy) for six weeks
Trial: 16859993
Drug: Diclofenac (both
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (both treatments)
Trial: 7889634
Drug: 1.1 ml/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1.1 ml/kg of 95% ethanol
Trial: 25662596
Drug: VCB regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: VCB regimen (cisplatin 80 mg/m², oral vinorelbine 60 mg/m², and bevacizumab 15 mg/kg) followed by DGB regimen (docetaxel 75 mg/m², gemcitabine 1100 mg/m², and bevacizumab 15 mg/kg)
Trial: 25662596
Drug: DCB regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: DCB regimen (cisplatin 80 mg/m², docetaxel 75 mg/m², and bevacizumab 15 mg/kg)
Trial: 23799908
Drug: Udenafil 50
RxNorm normalized name: udenafil
DrugBank: Udenafil (DB06267)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Udenafil 50 mg twice daily for 4 weeks, then 100 mg twice daily for 8 weeks
Trial: 22938690
Drug: Mannose-binding lectin
RxNorm normalized name: Mannose-binding lectin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mannose-binding lectin deficiency (MBL levels ≤ 500 ng/ml)
Trial: 17668527
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 5%/clindamycin 1% gel as monotherapy
Trial: 17668527
Drug: Topical benzoyl
RxNorm normalized name: benzoyl peroxide Topical Cream
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Topical benzoyl peroxide 5%/clindamycin 1% gel in combination with adapalene gel
Trial: 15496273
Drug: Granulocyte colony-stimulating
RxNorm normalized name: Granulocyte colony-stimulating factor lenograstim
DrugBank: Lenograstim (DB13144)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Granulocyte colony-stimulating factor (G-CSF) for stem cell mobilization
Trial: 28834483
Drug: Intensive treatment
RxNorm normalized name: Head & Shoulders Intensive Treatment
DrugBank: Selenium Sulfide (DB00971)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intensive treatment (target systolic blood pressure < 120 mm Hg)
Trial: 28834483
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment (target systolic blood pressure < 140 mm Hg)
Trial: 18324527
Drug: Tomato extract
RxNorm normalized name: TOMATO EXTRACT CONTAINING LYCOPENE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato extract (45 mg lycopene/day)
Trial: 18324527
Drug: Tomato juice
RxNorm normalized name: TOMATO JUICE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tomato juice (45 mg lycopene/day)
Trial: 17163232
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 mg once daily (regimen A)
Trial: 17163232
Drug: Hydrochlorothiazide 25
RxNorm normalized name: hydrochlorothiazide 25 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydrochlorothiazide 25 mg once daily (regimen B)
Trial: 17163232
Drug: Olmesartan medoxomil
RxNorm normalized name: Olmesartan Medoxomil
DrugBank: Olmesartan (DB00275)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Olmesartan medoxomil 20 mg once daily plus hydrochlorothiazide 25 mg once daily (regimen C)
Trial: 14604159
Drug: 1 year
RxNorm normalized name: COVID vacc 2024-2025 (5-11 years) (Pfizer)/PF 10 mcg/0.3 mL INTRAMUSC VIAL (ML)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 year of anti-epileptic drug therapy (AED)
Trial: 14604159
Drug: 2 years
RxNorm normalized name: Childrens Panadol 5 - 12 Years
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 2 years of anti-epileptic drug therapy (AED)
Trial: 14604159
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of persistent/calcified CT lesion and abnormal EEG prior to AED withdrawal
Trial: 14604159
Drug: 1 vs.
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 vs. 2 years of AED therapy
Trial: 10985512
Drug: Atropine 500
RxNorm normalized name: Atropine
DrugBank: Atropine (DB00572)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Atropine 500 mcg intramuscularly
Trial: 10985512
Drug: 0.9% saline
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.9% saline 1 mL intramuscularly
Trial: 8874574
Drug: Pre-incisional infiltration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pre-incisional infiltration with bupivacaine 2.5mg/ml, 1mg/kg after induction of general anaesthesia
Trial: 8874574
Drug: Post-incisional infiltration
RxNorm normalized name: post oak pollen extract
DrugBank: Quercus stellata pollen (DB10888)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Post-incisional infiltration with bupivacaine 2.5mg/ml, 1mg/kg after surgery
Trial: 8874574
Drug: Both groups
RxNorm normalized name: Streptococcus viridans group
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both groups received paracetamol 15-20 mg/kg rectally when admitted to the recovery ward
Trial: 4001842
Drug: 1 g
RxNorm normalized name: Molds 1 g
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 1 g of unconjugated chenodeoxycholic acid (CDA)
Trial: 22622852
Drug: Oral oxycodone
RxNorm normalized name: oxycodone Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral oxycodone (20 mg)
Trial: 22622852
Drug: Intravenous piritramide
RxNorm normalized name: piritramide
DrugBank: Piritramide (DB12492)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous piritramide PCA (2 mg piritramide/ml 0.9 % saline)
Trial: 22622852
Drug: Both treatments
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both treatments (oral oxycodone and PCA)
Trial: 14674116
Drug: Iscador QuS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Iscador QuS administered s.c. twice a week for 3 months
Trial: 14674116
Drug: Intron A
RxNorm normalized name: Intron A
DrugBank: Interferon alfa-2b (DB00105)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intron A administered twice a week in cervical injections for 3 months
Trial: 29664106
Drug: Therapeutic exercise
RxNorm normalized name: Moisturel Therapeutic
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Therapeutic exercise alone (control group with saline injection)
Trial: 29664106
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (saline injection) vs Hyaluronate
Trial: 28827103
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg per day
Trial: 28827103
Drug: Bicalutamide 50
RxNorm normalized name: bicalutamide 50 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bicalutamide 50 mg per day
Trial: 11576818
Drug: Prescription from
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prescription from a gynecologist
Trial: 11576818
Drug: Monoamine oxidase
RxNorm normalized name: Monoamine oxidase
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Monoamine oxidase inhibitors (MAOI) or selective serotonin reuptake inhibitors (SSRI) antidepressants 3 months prior to initiation
Trial: 8582196
Drug: Oestrogen-based hormone
RxNorm normalized name: Parathyroid Hormone
DrugBank: Parathyroid hormone (DB05829)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Oestrogen-based hormone replacement therapy
Trial: 2570798
Drug: Hydroxyzine, 25
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyzine, 25 mg twice daily
Trial: 31576607
Drug: Almond consumption
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Almond consumption (20% of daily energy for 16 weeks)
Trial: 18753185
Drug: Proton Pump
RxNorm normalized name: Proton pump inhibitor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Proton Pump Inhibitor (PPI), n=81
Trial: 18753185
Drug: Histamine-2 receptor
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Histamine-2 receptor antagonist (H2RA), n=19
Trial: 11010599
Drug: Maximal inspiratory
RxNorm normalized name: Spirulina maxima preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Maximal inspiratory effort (targeted peak inhalation flow 30 L/min)
Trial: 11010599
Drug: Submaximal inspiratory
RxNorm normalized name: respiratory syncytial virus pre-fusion F protein Injection [Arexvy]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Submaximal inspiratory effort (targeted peak inhalation flow 15 L/min)
Trial: 9283989
Drug: Astemizole 10
RxNorm normalized name: astemizole 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Astemizole 10 mg once daily
Trial: 8356856
Drug: Morphine (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Morphine (100 micrograms/kg)
Trial: 3322310
Drug: 3-palmitoyl-(+)‐catechin at
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3-palmitoyl-(+)‐catechin at a dose of 1500 mg daily (500 mg t.d.s.) for 3 months
Trial: 18678842
Drug: Rapid HIV
RxNorm normalized name: Abreva Rapid Pain Relief
DrugBank: Glycerin (DB09462)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rapid HIV testing with the OraQuick ADVANCE Rapid HIV‐1/2 Antibody Test
Trial: 18678842
Drug: Reactive oral
RxNorm normalized name: MedActive Rinse Oral Liquid Product
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Reactive oral OraQuick HIV screening test
Trial: 10223771
Drug: 16 g
RxNorm normalized name: Maltsupex, 16 g/15 mL oral liquid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 16 g of 5% ibuprofen gel (topical administration)
Trial: 1997515
Drug: 13‐min insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 13‐min insulin pulses (1.3 mU kg‐1 min‐1, 2 min on and 11 min off)
Trial: 1997515
Drug: 26‐min insulin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 26‐min insulin pulses (2.6 mU kg‐1 min‐1, 2 min on and 24 min off)
Trial: 1997515
Drug: Continuous insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Continuous insulin (0.2 mU kg‐1 min‐1)
Trial: 6555065
Drug: Dexamethasone administration
RxNorm normalized name: Dexamethasone
DrugBank: Dexamethasone acetate (DB14649)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Dexamethasone administration for 3 days
Trial: 31242981
Drug: Tualang honey
RxNorm normalized name: Honey
DrugBank: Honey (DB14242)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tualang honey 20mg daily for 8 weeks
Trial: 31242981
Drug: Vitamin C
RxNorm normalized name: Vitamin C
DrugBank: Sodium ascorbate (DB14482)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vitamin C 100mg daily for 8 weeks
Trial: 27206952
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl 4 g/day (MARINE)
Trial: 27206952
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl 4 g/day (ANCHOR)
Trial: 27206952
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl 4 g/day (ANCHOR, higher-efficacy group)
Trial: 27206952
Drug: Icosapent ethyl
RxNorm normalized name: Icosapent Ethyl
DrugBank: Icosapent ethyl (DB08887)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: Icosapent ethyl 4 g/day (ANCHOR, medium-efficacy group)
Trial: 19514187
Drug: NGF injection
RxNorm normalized name: Panthenol 1 g in 100 mL TOPICAL SOLUTION [NGF 574H HAIR]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: NGF injection at Yifeng (TE 17) and Wangu (GB 12)
Trial: 19514187
Drug: Xibiling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Xibiling and adenosine triphosphate (ATP) orally, and intramuscular injection with VB1 and VB12
Trial: 17766700
Drug: Enzastaurin (single
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (single doses 2-400 mg)
Trial: 17766700
Drug: Enzastaurin (multiple
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enzastaurin (multiple doses 25-400 mg)
Trial: 7909866
Drug: Postoperative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Postoperative treatment with 500 mg of 17‐1A antibody, followed by four 100 mg infusions each month
Trial: 27451879
Drug: Rikkunshito (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Rikkunshito (2.5 g before every meal for 48 weeks)
Trial: 22419702
Drug: Metformin (1000
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Metformin (1000 mg two times daily for obese women; 500 mg + 1000 mg daily for nonobese)